Description: Entia Biosciences, Inc. develops pharmaceutical-grade organic compounds, including a foundational compound called ErgoD2. The Company also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. The Company's ErgoD2 formulations utilize organically cultivated specialty mushrooms available from various domestic and international suppliers. These mushroom-based products are generally regarded as safe (GRAS). The Company's market and scientific research has identified mushroom species and suppliers to provide the nutritional profiles for its ErgoD2 formulations.
Home Page: www.entiabio.com
13565 SW Tualatin-Sherwood Road
Sherwood,
OR
97140
United States
Phone:
971-228-0709
Officers
| Name | Title |
|---|---|
| Dr. Marvin S. Hausman M.D. | Chairman and Chief Science & Technology Officer |
| Mr. Timothy A. Timmins | CEO & Pres |
| Mr. Elliot A. L. Shelton | Sec. and Director |
| William Meyer | Head of Production |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0.8876 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |